Non Small Cell Lung CancerPhase 1NCT07899801
A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 study testing Zanidatamab and Zongertinib in people with Non Small Cell Lung Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
This is a Phase Ia/Ib, open-label study evaluating the concurrent administration of zanidatamab and zongertinib in patients with advanced, unresectable, or metastatic non-small lung cancer harboring HER2 alterations. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non Small Cell Lung Cancer
- What is being tested?
- Zanidatamab and Zongertinib
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Apr 2027to 7 Dec 2030
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years at the time of consent.
- Histologically or cytologically confirmed diagnosis of an advanced, unresectable and/or metastatic non-small cell lung cancer (NSCLC).
- Baseline archival tumor tissue available, either from primary or metastatic sites. If archival material is not available, a fresh tumor biopsy should be performed if feasible and if the procedure poses no significant risk for the participant.
- Next generation sequencing (NGS) test documenting activating HER2 mutation in the tyrosine kinase domain assessed by a Clinical Laboratory Improvement Amendments (CLIA)-certified (United States [US] sites) or an equally accredited (outside of the US) local laboratory.
- Patients may be treatment-naïve in the advanced/metastatic setting (limited to a maximum of 12 patients) or may have received prior systemic therapy for advanced/metastatic disease. Prior treatment with HER2-targeted agents (including sevabertinib, zongertinib, and trastuzumab deruxtecan), cytotoxic chemotherapy, and immunotherapy is allowed.
- Must have at least one measurable cancer lesion according to Response Evaluation Criteria In Solid Tumors (RECIST)
Show all 28Show fewer
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Ability to take pills or capsules by mouth.
- Life expectancy of at least 12 weeks at the start of treatment in the opinion of the investigator.
- Patients must have adequate bone marrow and organ functions as defined:
- Hemoglobin ≥9 g/dL
- ANC ≥1.0 x 109 /L
- Platelets ≥75 x 10 ⁹ /L
- AST and ALT ≤3 x ULN if no demonstrable liver metastases, or otherwise ≤ 5 x ULN if transaminase elevation is attributable to liver metastases.
- Total bilirubin ≤1.5 x ULN; subjects with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits
- Serum creatinine <1.5 x ULN or calculated or estimated glomerular filtration rate >50 mL/min/1.73 m2 calculated using the Chronic Kidney Disease Epidemiology (CKD-EPI) formula
- Recovered from any previous therapy-related toxicity to CTCAE Grade 1 or lower at start of treatment (except for alopecia, stable sensory neuropathy and hypothyroidism).
- The effects of zanidatamab in combination with zongertinib on the developing human fetus are unknown. For this reason and because these agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to treatment initiation and for the duration of study treatment and for at least 4 months after the last dose of study intervention. (Refer to Pregnancy Assessment Policy UT MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:
- Postmenopausal (no menses in greater than or equal to 12 consecutive months).
- History of hysterectomy or bilateral salpingo-oophorectomy.
- Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
- History of bilateral tubal ligation or another surgical sterilization procedure
- Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
- Men treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study treatment and for at least 4 months after the last dose of study intervention.
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured.
- For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
- Ability to understand and the willingness to sign a written informed consent document.
- CNS metastasis are allowed as long as asymptomatic and stable - defined as patients who are either off steroids or on a low dose (prednisone <10 mg/day), with no neurological symptoms and no evidence of radiographic progression for at least 2 weeks prior to the study screening.
Who cannot join
- Prior or concurrent malignancy whose natural history or treatment has, in the opinion of the investigator or medical monitor, the potential to interfere with the safety or efficacy assessment of the investigational regimen.
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (have residual toxicities > Grade 1) except for alopecia, stable neuropathy, hypothyroidism and parameters superseded by other eligibility criteria [e.g., laboratory parameters]).
- Any of the following cardiac criteria:
- Baseline left ventricular ejection fraction (LVEF) < 50% or history of symptomatic congestive heart failure (New York Heart Association Class II to IV).
- Any Grade 2 or higher CHF related to a prior anti-cancer therapy. If grade 1 CHF occurred with prior treatment, it needs to be completely resolved prior to enrollment
- Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval >250msec
Show all 18Show fewer
- Prolonged QTc interval (>470 milliseconds for women and >450 milliseconds for men), or medical history of congenital Long QT Syndrome.
- The patient has experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 6 months prior to first dose of protocol therapy.
- Any evidence of severe or uncontrolled systemic diseases. Screening for chronic conditions is not required.
- Presence or history of uncontrolled or symptomatic brain metastases, unless considered stable by the investigator - defined as patients who are either off steroids or on a low dose (prednisone <10 mg/day), with no neurological symptoms.
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of zongertinib.
- Pregnant women are excluded from this study because zanidatamab in combination with zongertinib is HER2-inhibiting antineoplastic class of agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with zanidatamab and zongertinib, breastfeeding should be discontinued if the mother is treated with either agent. These potential risks may also apply to other agents used in this study..
- Patients not expected to comply with the protocol requirements or not expected to complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the patient an unreliable trial participant)
- History of life-threatening hypersensitivity to monoclonal antibodies or to recombinant proteins or excipients in drug formulation.
- Active or history of >Grade 2 interstitial lung disease/pneumonitis.
- Patients who are receiving any other investigational agents
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
- Patients with psychiatric illness/social situations that would limit compliance with study requirements.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
UT MD Anderson
Houston, Texas, 77030
Haniel A Araujo, MD, 346-722-1132, haaraujo@mdanderson.org
Haniel A Araujo, MD
About this study
This is a Phase Ia/Ib, open-label study evaluating the concurrent administration of zanidatamab and zongertinib in patients with advanced, unresectable, or metastatic non-small lung cancer harboring HER2 alterations.
Read the detailed description
Primary Objectives:
The primary objective of the study is to evaluate safety and tolerability of zongertinib in combination with zanidatamab in patients with HER2-mutant NSCLC.
The co-primary endpoints will be the incidence of DLTs during the first 21 days in Part 1 (safety lead-in) to determine the recommended dose of zongertinib in combination with zanidatamab; and the incidence of Treatment-Emergent Adverse Events (TEAEs) during the entire treatment period of the study (part 1 and 2)
Secondary Objectives:
- Determine the confirmed objective response rate (ORR) as per RECIST v1.1 with zanidatamab and zongertinib combination with efficacy endpoint confirmed ORR
- Determine the overall survival (OS) with zanidatamab and zongertinib combination with time to event endpoint OS
- Determine the progression-free survival (PFS) as per RECIST v1.1 t with zanidatamab and zongertinib combination with time to event endpoint PFS
- Determine the disease control rate (DCR) as per RECIST v1.1 t with zanidatamab and zongertinib combination with categorical efficacy endpoint DCR
- Determine the Duration of response (DOR) with zanidatamab and zongertinib combination with durability endpoint DOR
- Number of participants with adverse events (AEs) and serious adverse events (SAEs) categorized by severity with zanidatamab and zongertinib combination with endpoint AE/SAE frequency and severity
- Number of participants with AEs leading to discontinuations and leading to dose reductions with endpoint tracking treatment modifications due to toxicity.
EXploratory Objectives:
- Explore the association of baseline comprehensive genomic profiling (MDA MAPP platform or other CLIA-certified next generation sequencing assays with complete coverage of all Erbb2 alterations) with clinical benefit in patients treated with zanidatamab and zongertinib combination
- Explore resistance mechanisms to the zanidatamab and zongertinib combination. At the time of disease progression, patients will undergo plasma collection for circulating tumor DNA (ctDNA) testing and a tissue biopsy to perform genomic and transcriptomic analyses to provide additional insights into putative resistance mechanisms.
- Correlate ctDNA clearance with treatment response. Serial ctDNA collections at baseline and during treatment will be analyzed to evaluate the relationship between ctDNA dynamics and therapeutic response.
- Study the biology of drug-tolerant, persistent cancer cells. Tissue and plasma samples collected during treatment will be used to investigate the underlying biology of drugtolerant persistent cancer cells
- Determine the immunomodulatory effects of zanidatamab and zongertinib combination in the tumor microenvironment.
- Conditions
- Non Small Cell Lung Cancer
- Being tested
- Zanidatamab, Zongertinib
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ZanidatamabDrug
Also called Ziihera
Given by intravenous infusion
ZongertinibDrug
Also called Hernexeos
Given by mouth
| Study group | Role | What they receive |
|---|---|---|
| Part 1 Safety Lead-In Cohort: Treatment with Zanidatamab + Zongertinib | Experimental | Participants will receive treatment on an outpatient basis Receives: Drug: Zanidatamab; Drug: Zongertinib |
| Part 2 Expansion Cohort: Treatment with Zanidatamab + Zongertinib | Experimental | Participants will receive treatment on an outpatient basis Receives: Drug: Zanidatamab; Drug: Zongertinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 6.0
Measured: Through study completion; an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2026
- Study start1 Apr 2027 (estimated)
- Primary completion7 Dec 2028 (estimated)
- Study completion7 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non Small Cell Lung CancerStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- Boehringer Ingelheim, Jazz Pharmaceuticals
- Responsible party
- Sponsor
- Investigators
- Haniel A Araujo, MD, Principal investigator, UT MD Anderspm
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07899801
- Sponsor's protocol ID
- 2026-0952
- Other IDs
- NCI-2026-08054
- Status last verified
- Oct 2026
- First submitted
- 26 Oct 2026
- Last updated
- 28 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)
- ClinicalTrials.gov ID
- NCT07899801
- Acronym / sponsor ID
- 2026-0952
- Conditions
- Non Small Cell Lung Cancer
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Collaborators
- Boehringer Ingelheim, Jazz Pharmaceuticals
- Study start
- 1 Apr 2027 (estimated)
- Primary completion
- 7 Dec 2028 (estimated)
- Study completion
- 7 Dec 2030 (estimated)
- First posted
- 28 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase Ia/Ib, open-label study evaluating the concurrent administration of zanidatamab and zongertinib in patients with advanced, unresectable, or metastatic non-small lung cancer harboring HER2 alterations.
Detailed description
Primary Objectives:
The primary objective of the study is to evaluate safety and tolerability of zongertinib in combination with zanidatamab in patients with HER2-mutant NSCLC.
The co-primary endpoints will be the incidence of DLTs during the first 21 days in Part 1 (safety lead-in) to determine the recommended dose of zongertinib in combination with zanidatamab; and the incidence of Treatment-Emergent Adverse Events (TEAEs) during the entire treatment period of the study (part 1 and 2)
Secondary Objectives:
- Determine the confirmed objective response rate (ORR) as per RECIST v1.1 with zanidatamab and zongertinib combination with efficacy endpoint confirmed ORR
- Determine the overall survival (OS) with zanidatamab and zongertinib combination with time to event endpoint OS
- Determine the progression-free survival (PFS) as per RECIST v1.1 t with zanidatamab and zongertinib combination with time to event endpoint PFS
- Determine the disease control rate (DCR) as per RECIST v1.1 t with zanidatamab and zongertinib combination with categorical efficacy endpoint DCR
- Determine the Duration of response (DOR) with zanidatamab and zongertinib combination with durability endpoint DOR
- Number of participants with adverse events (AEs) and serious adverse events (SAEs) categorized by severity with zanidatamab and zongertinib combination with endpoint AE/SAE frequency and severity
- Number of participants with AEs leading to discontinuations and leading to dose reductions with endpoint tracking treatment modifications due to toxicity.
EXploratory Objectives:
- Explore the association of baseline comprehensive genomic profiling (MDA MAPP platform or other CLIA-certified next generation sequencing assays with complete coverage of all Erbb2 alterations) with clinical benefit in patients treated with zanidatamab and zongertinib combination
- Explore resistance mechanisms to the zanidatamab and zongertinib combination. At the time of disease progression, patients will undergo plasma collection for circulating tumor DNA (ctDNA) testing and a tissue biopsy to perform genomic and transcriptomic analyses to provide additional insights into putative resistance mechanisms.
- Correlate ctDNA clearance with treatment response. Serial ctDNA collections at baseline and during treatment will be analyzed to evaluate the relationship between ctDNA dynamics and therapeutic response.
- Study the biology of drug-tolerant, persistent cancer cells. Tissue and plasma samples collected during treatment will be used to investigate the underlying biology of drugtolerant persistent cancer cells
- Determine the immunomodulatory effects of zanidatamab and zongertinib combination in the tumor microenvironment.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Part 1 Safety Lead-In Cohort: Treatment with Zanidatamab + Zongertinib | Experimental | Drug: Zanidatamab, Drug: ZongertinibParticipants will receive treatment on an outpatient basis |
| Part 2 Expansion Cohort: Treatment with Zanidatamab + Zongertinib | Experimental | Drug: Zanidatamab, Drug: ZongertinibParticipants will receive treatment on an outpatient basis |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (28 listed)
- Age ≥ 18 years at the time of consent.
- Histologically or cytologically confirmed diagnosis of an advanced, unresectable and/or metastatic non-small cell lung cancer (NSCLC).
- Baseline archival tumor tissue available, either from primary or metastatic sites. If archival material is not available, a fresh tumor biopsy should be performed if feasible and if the procedure poses no significant risk for the participant.
- Next generation sequencing (NGS) test documenting activating HER2 mutation in the tyrosine kinase domain assessed by a Clinical Laboratory Improvement Amendments (CLIA)-certified (United States [US] sites) or an equally accredited (outside of the US) local laboratory.
- Patients may be treatment-naïve in the advanced/metastatic setting (limited to a maximum of 12 patients) or may have received prior systemic therapy for advanced/metastatic disease. Prior treatment with HER2-targeted agents (including sevabertinib, zongertinib, and trastuzumab deruxtecan), cytotoxic chemotherapy, and immunotherapy is allowed.
Key exclusion criteria (18 listed)
- Prior or concurrent malignancy whose natural history or treatment has, in the opinion of the investigator or medical monitor, the potential to interfere with the safety or efficacy assessment of the investigational regimen.
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (have residual toxicities > Grade 1) except for alopecia, stable neuropathy, hypothyroidism and parameters superseded by other eligibility criteria [e.g., laboratory parameters]).
- Any of the following cardiac criteria:
- Any evidence of severe or uncontrolled systemic diseases. Screening for chronic conditions is not required.
- Presence or history of uncontrolled or symptomatic brain metastases, unless considered stable by the investigator - defined as patients who are either off steroids or on a low dose (prednisone <10 mg/day), with no neurological symptoms.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ZanidatamabAlso: ZiiheraGiven by intravenous infusion | Drug | Part 1 Safety Lead-In Cohort: Treatment with Zanidatamab + Zongertinib, Part 2 Expansion Cohort: Treatment with Zanidatamab + Zongertinib |
| ZongertinibAlso: HernexeosGiven by mouth | Drug | Part 1 Safety Lead-In Cohort: Treatment with Zanidatamab + Zongertinib, Part 2 Expansion Cohort: Treatment with Zanidatamab + Zongertinib |
Primary outcome
Safety and Adverse Events (AEs)
Time frame: Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 6.0
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- UT MD Anderson WebsiteLink provided by the sponsor.
Related trials for Non Small Cell Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Haniel A Araujo, MD principal investigator
UT MD Anderspm
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Zanidatamab and Zongertinib in people with Non Small Cell Lung Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 28 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Haniel A Araujo, MD (346-722-1132, haaraujo@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and Adverse Events (AEs) (time frame: Through study completion; an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.